news

British Columbia first province to switch patients to biosimilars

20
SHARES

British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.

This new policy is from Canadian province British Columbia’s public PharmaCare programme and targets Janssen’s Remicade and Amgen’s Enbrel which treat arthritis, among other conditions, and Sanofi’s long-acting insulin Lantus. This will save an estimated C$96.6 million over three years.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

It is the first of its kind in a Canadian public plan and could pave the way for similar programmes across the country.

“Biosimilars are a necessary step to ensure PharmaCare provides existing coverage for more people and funds new drugs well into the future,” said the British Columbia government in a statement.

As reported in Reuters, Sanofi Canada said it was disappointed and regretted that BC “did not take the opportunity to find an alternative solution to preserve this treatment option” – Janssen and Amgen did not immediately respond to requests for comment by the publication.

In Canada, pharmacists cannot swap biosimilars in for their predecessors once patents expire, the way they can with generics. Doctors must specifically prescribe the biosimilar, and they have been slow to do that.

The United States has also been slow to adopt biosimilars. Regulators have lagged Europe in approving the drugs, and a complex system of rebates offered to insurers by drugmakers has created barriers to use.

Canadian law says provincial governments must cover medically necessary care by doctors, including treatment in hospital, but prescription drugs are paid for through a patchwork of public and employer-based insurance plans.

The British Columbian government also announced that it would begin covering two newer biologic drugs: Boehringer Ingelheim and Eli Lilly’s Jardiance, a diabetes drug, and Eli Lilly’s Taltz, which treats psoriatic arthritis.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via